Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Metastatic, histologically or cytologically proven breast cancer.~* At least one bi-dimensionally measurable lesion.~* Previous treatment with chemotherapy as first line for metastatic disease is mandatory especially with anthracyclines +/- the Taxanes.~* Treatment as adjuvant is allowed.~* World Health Organization-ECOG performance status 0-2.~* Adequate renal function (Creatinine \<= 1.4 or Creatinine clearance \>= 30 ml/min)~* Adequate hepatic function (Liver Function Tests not more than 3 times the normal values)~* Adequate bone marrow reserve is required (Neutrophils (PMN) \>= 2000/mm2 and Platelets \>= 100,000/mm2)~* Patient who will receive Herceptin should have an over-expression of HER2-neu.~Exclusion Criteria:~* Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria grade more than one).~* Pregnant or breast-feeding.~* History of prior malignancies (with the exception of excised cervical carcinoma-in-situ or non-melanoma cell skin carcinoma).~* Receiving or had received, any treatment with experimental drugs.~* Had known brain or leptomeningeal involvement.~* Had a serious medical condition like congestive heart failure or an Ejection Fraction ≥ 40 %.~* The presence of bone as a sole site of metastasis.~* Radiation therapy to all areas of measurable disease less than four weeks before treatment.~* Creatinine two times above the normal range~* Hypercalcemia~* Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion - Ascites - Pericardial effusion.~* Concomitant steroid intake for \> 4 weeks~* Bilirubin two times above the normal range~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).